Blog
RSS FeedPosted by Michael Wonder on 23 Feb 2017
Uncertainty on R&D tax incentive causing real harm
23 February 2017 - Constant reviews and recent changes to the Research and Development (R&D) Tax Incentive are jeopardising Australian ...
Posted by Michael Wonder on 21 Feb 2017
AusBiotech suggests FSANZ amend cost recovery plan
21 February 2017 - AusBiotech has responded to Food Standards Australia New Zealand (FSANZ) call for comment on the draft ...
Posted by Michael Wonder on 20 Feb 2017
Big pharma funding biases drug trials in favour of a sponsor's product: review
21 February 2017 - Drug and device trial studies that are sponsored by the pharmaceutical industry are more likely to ...
Posted by Michael Wonder on 18 Feb 2017
Will drug companies' price-transparency efforts fall short?
16 February 2017 - In January, 2017, Merck disclosed its aggregate drug price increases since 2010 in an annual Corporate Responsibility ...
Posted by Michael Wonder on 15 Feb 2017
Drug makers riled amid calls for yearly review of drug costs
15 February 2017 - The pharmaceutical industry is protesting a health ministry plan to review government-set drug prices annually, saying ...
Posted by Michael Wonder on 07 Feb 2017
Privatised pharmaceutical innovation vs access to essential medicines: a global framework for equitable sharing of benefits
7 February 2017 - The effect of the current privatized model of pharmaceutical innovation on the development and affordability of lifesaving ...
Posted by Michael Wonder on 03 Feb 2017
U.S. House panel to take up bill to spur generic drug development
2 February 2017 - A U.S. House of Representatives subcommittee will take up bipartisan legislation next week to foster generic ...
Posted by Michael Wonder on 02 Feb 2017
Outcomes of early health technology assessment dialogues in medicinal product development
2 February 2017 - The development of medicinal products has been shifting towards a value-driven model. ...
Posted by Michael Wonder on 02 Feb 2017
Drug development challenges for small biopharmaceutical companies
1 February 2017 - Small biopharmaceutical companies are becoming increasingly important as drivers of innovation in drug development. ...
Posted by Michael Wonder on 02 Feb 2017
AusBiotech consults biotech CEOs on industry advocacy
2 February 2017 - AusBiotech has launched its annual consultation of membership issues, calling for leaders of biotechnology companies to ...
Posted by Michael Wonder on 01 Feb 2017
Pharmaceutical patent challenges: company strategies and litigation outcomes
31 January 2017 - The pharmaceutical industry has experienced a large number of patent challenges in recent years. ...
Posted by Michael Wonder on 01 Feb 2017
Roche remains 'committed' to US despite Trump's crackdown on drug prices
1 February 2017 - Roche remains committed to the U.S. despite President Donald Trump's pledges to crackdown on pharmaceutical companies ...
Posted by Michael Wonder on 01 Feb 2017
Eli Lilly CEO: We're not jacking up our drug costs for profit
1 February 2017 - Eli Lilly CEO: Looking for 'market based solutions' on drug costs Eli Lilly CEO: Looking for 'market ...
Posted by Michael Wonder on 01 Feb 2017
Trump wants to blow up the FDA. The drug industry? Not so much
1 February 2017 - President Donald Trump wants to remake the FDA. ...
Posted by Michael Wonder on 01 Feb 2017
Can a butterfly cause a typhoon? Just ask Innate Immunotherapeutics
1 February 2017 - Can the flutter of a butterfly in South America, or in this case Oceania, really cause ...